Class C β-Lactamases: An increasing problem worldwide

Reviews and Research in Medical Microbiology

Volumn 15, Issue 4, 2004, Pages 141-152

  Beceiro, Alejandro ^a   Bou, German ^a  

^a Statistics Department   (Spain)

Author keywords

AmpC enzymes; Inhibitors; lactamase profile

Indexed keywords

ALEFOTELAN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BETA LACTAMASE AMPC; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CARBENICILLIN; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFPIROME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CEPHAMYCIN DERIVATIVE; CLAVULANIC ACID; COTRIMOXAZOLE; IMIPENEM; LATAMOXEF; MEROPENEM; OXACILLIN; PIPERACILLIN; QUINOLONE DERIVATIVE; RESERPINE; SULBACTAM; TAZOBACTAM; TICARCILLIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; BACTERIAL CHROMOSOME; BACTERIAL INFECTION; ENZYME MECHANISM; ENZYME SPECIFICITY; GRAM NEGATIVE BACTERIUM; HYDROLYSIS; MUTATION; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

EID: 12244307473     PISSN: 0954139X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00013542-200410000-00003     Document Type: Review

References (105)

1. Waxman DJ, Strominger JL. Penicillin-binding proteins and the mechanism of action of beta-lactam antibiotics. Annu Rev Biochem 1983, 52:825-869.
2. Nikaido H, Vaara M. Molecular basis of bacterial outer membrane permeability. Mol Biol Rev 2003, 62:593-656.
3. Hancock RE. The bacterial outer membrane as a drug barrier. Trends Microbiol 1997, 5:37-42.
4. Sykes RB, Matthew M. The beta-lactamases of gram-negative bacteria and their role in resistance to beta-lactam antibiotics. J Antimicrob Chemother 1976, 2:115-157.
5. Ambler RP. The structure of beta-lactamases. Philos Trans R Soc Lond B Biol Sci 1980, 289:321-331.
6. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995, 39:1211-1233.
7. Sanders CC. Chromosomal cephalosporinases responsible for multiple resistance to newer beta-lactam antibiotics. Annu Rev Microbiol 1987, 41:573-593.
8. Fleming PC, Goldner M, Glass DG. Observations on the nature, distribution, and significance of cephalosporinase. Lancet 1963, 1:1399-1401.
9. Hamilton-Miller JM, Smith JT. Inhibition of penicillinases from gram-positive and gram-negative bacteria by substrate analogues. Nature 1964, 201:999-1001.
10. Hamilton-Miller JM, Smith JT, Knox R. Interaction of cephaloridine with penicillinase-producing gram-negative bacteria. Nature 1965, 208:235-237.
11. Sabath LD, Jago M, Abraham EP. Cephalosporinase and penicillinase activities of a beta-lactamase from Pseudomonas pyocyanea. Biochem J 1965, 96:739-752.
12. Collatz E, Gutmann L, Williamson R, Acar JF. Development of resistance to beta-lactam antibiotics with special reference to third-generation cephalosporins. J Antimicrob Chemother 1984, 14(Suppl B):13-21.
13. Weinstein RA. Occurrence of cefotaxime-resistant Enterobacter during therapy of cardiac surgery patients. Chemioterapia 1985, 4:110-112.
14. Perronne C, Regnier B, Legrand P, Bure A, Frottier J, Vilde JL, Vachon F. Failure of new beta-lactam antibiotics in the treatment of severe Enterobacter cloacae infections. Presse Med 1986 Oct, 15:1813-1818.
15. Pedersen SS, Koch C, Hoiby N, Rosendal K. An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre. J Antimicrob Chemother 1986, 17:505-516.
16. Nichols WW, Milne LM. Derepressed beta-lactamase synthesis in strains of Pseudomonas aeruginosa isolated from patients with cystic fibrosis. J Antimicrob Chemother 1986, 18:549-550.
17. Medeiros AA, Hare R, Papa E, Adam C, Miller GH. Gram-negative bacilli resistant to third-generation cephalosporins: beta-lactamase characterization and susceptibility to Sch 34343. J Antimicrob Chemother 1985, 15 Suppl C:119-132.
18. Philippon A, Arlet G, Lagrange PH. Origin and impact of plasmid-mediated extended-spectrum beta-lactamases. Eur J Clin Microbiol Infect Dis 1994, 13 (Suppl 1):S17-S29.
19. Livermore DM. Beta-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995, 8:557-584.
20. Bobrowski MM, Matthew M, Barth PT, Datta N, Grinter NJ, Jacob AE, et al. Plasmid-determined beta-lactamase indistinguishable from the chromosomal beta-lactamase of Escherichia coli. J Bacteriol 1976, 125:149-157.
21. Levesque R, Roy PH, Letarte R, Pechere JC. A plasmid-mediated cephalosporinase from Achromobacter species. J Infect Dis 1982, 145:753-761.
22. Bauernfeind A, Chong Y, Lee K. Plasmid-encoded AmpC beta-lactamases: how far have we gone 10 years after the discovery? Yonsei Med J 1998, 39:520-525.
23. Papanicolaou GA, Medeiros AA, Jacoby GA. Novel plasmid-mediated beta-lactamase (MIR-1) conferring resistance to oxyimino- and alpha-methoxy beta-lactams in clinical isolates of Klebsiella pneumomae. Antimicrob Agents Chemotner 1990, 34:2200-2209.
24. Philippon A, Arlet G, Jacoby GA. Plasmid-determined AmpC-type beta-lactamases. Antimicrob Agents Chemother 2002, 46:1-11.
25. Lindberg F, Westman L, Normark S. Regulatory components in Citrobacter freundii ampC beta-lactamase induction. Proc Natl Acad Sci USA 1985, 82:4620-4624.
26. Corvec S, Caroff N, Espaze E, Marraillac J, Reynaud A. -11 Mutation in the ampC promoter increasing resistance to beta-lactams in a clinical Escherichia coli strain. Antimicrob Agents Chemother 2002, 46:3265-3267.
27. Caroff N, Espaze E, Gautreau D, Richet H, Reynaud A. Analysis of the effects of -42 and -32 ampC promoter mutations in clinical isolates of Escherichia coli hyperproducing ampC. J Antimicrob Chemother 2000, 45:783-788.
28. Jaurin B, Grundstrom T, Edlund T, Normark S. The E. coli beta-lactamase attenuator mediates growth rate-dependent regulation. Nature 1981, 290:221-225.
29. Siu LK, Lu PL, Chen JY, Lin FM, Chang SC. High-level expression of ampC beta-lactamase due to insertion of nucleotides between -10 and -35 promoter sequences in Escherichia coli clinical isolates: cases not responsive to extended-spectrum-cephalosporin treatment. Antimicrob Agents Chemother 2003, 47:2138-2144.
30. Corvec S, Caroff N, Espaze E, Giraudeau C, Drugeon H, Reynaud A. AmpC cephalosporinase hyperproduction in Acinetobacter baumannii clinical strains. J Antimicrob Chemother 2003, 52:629-635.
31. Segal H, Nelson EC, Elisha BG. Genetic environment and transcription of ampC in an Acinetobacter baumannii clinical isolate. Antimicrob Agents Chemother 2004, 48:612-614.
32. Goodell EW. Recycling of murein by Escherichia coli. J Bacteriol 1985, 163:305-310.
33. Hanson ND, Sanders CC. Regulation of inducible AmpC beta-lactamase expression among Enterobacteriaceae. Curr Pharm Des 1999, 5:881 -894. Review.
34. Lindquist S, Galleni M, Lindberg F, Normark S. Signalling proteins in enterobacterial AmpC beta-lactamase regulation. Mol Microbiol 1989, 3:1091-1102.
35. Dietz H, Pfeifle D, Wiedemann B. The signal molecule for beta-lactamase induction in Enterobacter cloacae is the anhydromuramyl-pentapeptide. Antimicrob Agents Chemother 1997, 41:2113-2120.
36. Jacobs C, Huang LJ, Bartowsky E, Normark S, Park JT. Bacterial cell wall recycling provides cytosolic muropeptides as effectors for beta-lactamase induction. EMBO J 1994, 13:4684-4694.
37. Livermore DM. Clinical significance of beta-lactamase induction and stable derepression in gram-negative rods. Eur J Clin Microbiol 1987, 6:439-445.
38. Bennett PM, Chopra I. Molecular basis of beta-lactamase induction in bacteria. Antimicrob Agents Chemother 1993, 37:153-158.
39. Lindberg F, Lindquist S, Normark S. Inactivation of the ampD gene causes semiconstitutive overproduction of the inducible Citrobacter freundii beta-lactamase. J Bacteriol 1987, 169:1923-1928.
40. Jones RN. Important and emerging beta-lactamase-mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn Microbiol Infect Dis 1998, 31:461-466.
41. Sanders CC, Bradford PA, Ehrhardt AF, Bush K, Young KD, Henderson TA, et al. Penicillin-binding proteins and induction of AmpC beta-lactamase. Antimicrob Agents Chemother 1997, 41:2013-2015.
42. Sahm DF, Storch G. AmpC beta-lactamases. Pediatr Infect Dis J 1998, 17:421-422.
43. Ballow CH, Schentag JJ. Trends in antibiotic utilization and bacterial resistance. Report of the National Nosocomial Resistance Surveillance Group. Diagn Microbiol Infect Dis 1992, 15(2 Suppl):37S-42S.
44. Glauser M. Empiric therapy of bacterial infections in patients with severe neutropenia. Diagn Microbiol Infect Dis 1998, 31:467-472.
45. Limaye AP, Gautom RK, Black D, Fritsche TR. Rapid emergence of resistance to cefepime during treatment. Clin Infect Dis 1997, 25:339-340.
46. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. Approved standard M7-A4. Wayne, PA: National Committee for Clinical Laboratory Standards, 1997.
47. Thomson KS. Controversies about extended-spectrum and AmpC beta-lactamases. Emerg Infect Dis 2001, 7:333-336.
48. Tzouvelekis LS, Vatopoulos AC, Katsanis G, Tzelepi E. Rare case of failure by an automated system to detect extended-spectrum beta-lactamase in a cephalosporin-resistant Klebsiella pneumoniae isolate. J Clin Microbiol 1999, 37:2388.
49. Thomson KS, Sanders CC, Moland ES. Use of microdilution panels with and without beta-lactamase inhibitors as a phenotypic test for beta-lactamase production among Escherichia coli. Klebsiella spp., Enterobacter spp., Citrobacter freundii, and Serratia marcescens. Antimicrob Agents Chemother 1999, 43:1393-400.
50. Conejo MC, Van der Hooft M, Fernández-Cuenca F, Pascual A, Martinez-Martinez L. Cefotetan (CTT)-Cloxacillin (CLX) synergy test for differentiation of Klebsiella pneumoniae (Kp) producing plasmid-mediated AmpC-Type β-lactamase(pACBL+) from strains producing extended-spectrum β-lactamases and deficient in porins (ESBL+/POR-), abstr. D-207. 43th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, September 2003 [abstracts 168].
51. Black JA, Thomson KS, Pitout JD. Use of beta-lactamase inhibitors in disk tests to detect plasmid-mediated AmpC beta-lactamases. J Clin Microbiol 2004, 42:2203-2206.
52. Yang YJ, Livermore DM. Interactions of meropenem with class I chromosomal beta-lactamases. J Antimicrob Chemother 1989, 24 (Suppl A):207-217.
53. Bush K, Macalintal C, Rasmussen BA, Lee VJ, Yang Y. Kinetic interactions of tazobactam with beta-lactamases from all major structural classes. Antimicrob Agents Chemother 1993, 37:851-858.
54. Akova M, Yang Y, Livermore DM. Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases. J Antimicrob Chemother 1990, 25:199-208.
55. Trehan I, Beadle BM, Shoichet BK. Inhibition of AmpC beta-lactamase through a destabilizing interaction in the active site. Biochemistry 2001, 40:7992-7999.
56. Beadle BM, Shoichet BK. Structural basis for imipenem inhibition of class C beta-lactamases. Antimicrob Agents Chemother 2002, 46:3978-3980.
57. Sakurai Y, Yoshida Y, Saitoh K, Nemoto M, Yamaguchi A, Sawai T. Characteristics of aztreonam as a substrate, inhibitor and inducer for beta-lactamases. J Antibiot 1990, 43:403-410.
58. Li XZ, Zhang L, Srikumar R, Poole K. Beta-lactamase inhibitors are substrates for the multidrug efflux pumps of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1998, 42:399-403.
59. Poirel L, Heritier C, Spicq C, Nordmann P. In vivo acquisition of high-level resistance to imipenem in Escherichla coli. J Clin Microbiol 2004, 42:3831-3833.
60. Heinze-Krauss I, Angehrn P, Charnas RL, Gubernator K, Gutknecht EM, Hubschwerlen C, et al. Structure-based design of beta-lactamase inhibitors. 1. Synthesis and evaluation of bridged monobactams. J Med Chem 1998, 41:3961-3971.
61. Livermore DM, Chen HY. Potentiation of beta-lactams against Pseudomonas aeruginosa strains by Ro 48-1256, a bridged monobactam inhibitor of AmpC beta-lactamases. J Antimicrob Chemother 1997, 40:335-343.
62. Nishida K, Kunugita C, Uji T, Higashitani F, Hyodo A, Unemi N, et al. In vitro and in vivo activities of Syn2190, a novel beta-lactamase inhibitor. Antimicrob Agents Chemother 1999, 43:1895-1900.
63. Babini GS, Livermore DM. Effect of conalbumin on the activity of Syn 2190, a 1,5 dihydroxy-4-pyridon monobactam inhibitor of AmpC beta-lactamases. J Antimicrob Chemother 2000, 45:105-109.
64. Nikaido H, Rosenberg EY. Cir and Fiu proteins in the outer membrane of Escherichia coli catalyze transport of monomeric catechols: study with beta-lactam antibiotics containing catechol and analogous groups. J Bacteriol 1990, 172:1361-1367.
65. Danes C, Navia MM, Ruiz J, Marco F, Jurado A, Jimenez de Anta MT, et al. Distribution of beta-lactamases in Acinetobacter baumannii clinical isolates and the effect of Syn 2190 (AmpC inhibitor) on the MICs of different beta-lactam antibiotics. J Antimicrob Chemother 2002, 50:261-264.
66. Richter HG, Angehrn P, Hubschwerlen C, Kania M, Page MG, Specklin JL, et al. Design, synthesis, and evaluation of 2 beta-alkenyl penam sulfone acids as inhibitors of beta-lactamases. J Med Chem 1996, 39:3712-3722.
67. Buynak JD, Doppalapudi VR, Rao AS, Nidamarthy SD, Adam G. The synthesis and evaluation of 2-substituted-7-(alkylidene)cephalosporin sulfones as beta-lactamase inhibitors. Bioorg Med Chem Lett 2000, 10:847-851.
68. Buynak JD, Rao AS, Doppalapudi VR, Adam G, Petersen PJ, Nidamarthy SD. The synthesis and evaluation of 6-alkylidene-2′beta-substituted penam sulfones as beta-lactamase inhibitors. Bioorg Med Chem Lett 1999, 9:1997-2002.
69. Bitha P, Li Z, Francisco GD, Yang Y, Petersen PJ, Lenoy E, Lin YI. 6-(1-Hydroxyalkyl))penam sulfone derivatives as inhibitors of class A and class C beta-lactamases II. Bioorg Med Chem Lett 1999, 9:997-1002.
70. Bitha P, Li Z, Francisco GD, Rasmussen BA, Lin YI. 6-(1-Hydroxyalkyl) penam sulfone derivatives as inhibitors of class A and class C beta-lactamases I. Bioorg Med Chem Lett 1999, 9:991-996.
71. Zhou XY, Kitzis MD, Acar JF, Gutmann L. Activity of the beta-lactamase inhibitor BRL 42715 against cephalosporinases produced by Enterobacteriaceae. J Antimicrob Chemother 1993, 31:473-480.
72. Muratani T, Yokota E, Nakane T, Inoue E, Mitsuhashi S. In-vitro evaluation of the four beta-lactamase inhibitors: BRL42715, clavulanic acid, sulbactam, and tazobactam. J Antimicrob Chemother 1993, 32:421-429.
73. Zhou XY, Kitzis MD, Gutmann L. Role of cephalosporinase in carbapenem resistance of clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1993, 37:1387-1389.
74. Satake S, Nakae T. Outer membrane permeability of beta-lactamase inhibitors in Pseudomonas aeruginosa. FEMS Microbiol Lett 1995, 129:251-254.
75. Li XZ, Zhang L, Srikumar R, Poole K. Beta-lactamase inhibitors are substrates for the multidrug efflux pumps of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1998, 42:399-403.
76. Powers RA, Blazquez J, Weston GS, Morosini MI, Baquero F, Shoichet BK. The complexed structure and antimicrobial activity of a non-beta-lactam inhibitor of AmpC beta-lactamase. Protein Sci 1999, 8:2330-2337.
77. Weston GS, Blazquez J, Baquero F, Shoichet BK. Structure-based enhancement of boronic acid-based inhibitors of AmpC beta-lactamase. J Med Chem 1998, 41:4577-86.
78. Buzzoni V, Blazquez J, Ferrari S, Calo S, Venturelli A, Costi MP. Aza-horonic acids as non-beta-lactam inhibitors of AmpC-beta-lactamase. Bioorg Med Chem Lett 2004, 14:3979-3983.
79. Morandi F, Caselli E, Morandi S, Focia PJ, Blazquez J, Shoichet BK, Prati F. Nanomolar inhibitors of AmpC beta-lactamase. J Am Chem Soc 2003, 125:685-695.
80. Mascaretti, AO. Bacterial resistance to β-lactam antibiotics and β-lactam inhibitors of β-lactamases, p. 171-198. In Oreste A. Mascaretti (ed). Bacterial Versus Antibacterial Agents. An Integrated Approach. Washington DC: ASM Press, 2003.
81. Rudgers GW, Huang W, Palzkill T. Binding properties of a peptide derived from beta-lactamase inhibitory protein. Antimicrob Agents Chemother 2001, 45:3279-3286.
82. Tondi D, Powers RA, Caselli E, Negri MC, Blazquez J, Costi MP, et al. Structure-based design and in-parallel synthesis of inhibitors of AmpC beta-lactamase. Chem Biol 2001, 8:593-611.
83. Massova I, Mobashery S. Kinship and diversification of bacterial penicillin-binding proteins and beta-lactamases. Antimicrob Agents Chemother 1998, 42:1-17.
84. Frere JM. Beta-lactamases and bacterial resistance to antibiotics. Mol Microbiol 1995, 16:385-395.
85. Lobkovsky E, Moews PC, Liu H, Zhao H, Frere JM, Knox JR. Evolution of an enzyme activity: crystallographic structure at 2-A resolution of cephalosporinase from the ampC gene of Enterobacter cloacae P99 and comparison with a class A penicillinase. Proc Natl Acad Sci USA 1993, 90:11257-11261.
86. Dubus A, Ledent P, Lamotte-Brasseur J, Frere JM. The roles of residues Tyr150, Glu272, and His314 in class C beta-lactamases. Proteins 1996, 25:473-485.
87. Oefner C, D'Arcy A, Daly JJ, Gubernator K, Charnas RL, Heinze I, et al. Refined crystal structure of beta-lactamase from Citrobacter freundii indicates a mechanism for beta-lactam hydrolysis. Nature 1990, 18:284-288.
88. Dubus A, Normark S, Kania M, Page MG. The role of tyrosine 150 in catalysis of beta-lactam hydrolysis by AmpC beta-lactamase from Escherichia coli investigated by site-directed mutagenesis. Biochemistry 1994, 33:8577-8586.
89. Tsukamoto K, Nishida N, Tsuruoka M, Sawai T. Function of the conserved triad residues in the class C beta-lactamase from Citrobacter freundii GN346. FEBS Lett 1990, 271:243-246.
90. Minasov G, Wang X, Shoichet BK. An ultrahigh resolution structure of TEM-1 beta-lactamase suggests a role for Glu166 as the general base in acylation. J Am Chem Soc 2002, 124:5333-5340.
91. Nukaga M, Tanimoto K, Tsukamoto K, Imajo S, Ishiguro M, Sawai T. A survey of a functional amino acid of class C beta-lactamase corresponding to Glu166 of class A beta-lactamases. FEBS Lett 1993, 332:93-98.
92. Nukaga M, Haruta S, Tanimoto K, Kogure K, Taniguchi K, Tamaki M, Sawai T. Molecular evolution of a class C beta-lactamase extending its substrate specificity. J Biol Chem 1995, 270:5729-5735.
93. Zhang Z, Yu Y, Musser JM, Palzkill T. Amino acid sequence determinants of extended spectrum cephalosporin hydrolysis by the class C P99 beta-lactamase. J Biol Chem 2001, 276:46568-46574.
94. Raimondi A, Sisto F, Nikaido H. Mutation in Serratia marcescens AmpC beta-lactamase producing high-level resistance to ceftazidime and cefpirome. Antimicrob Agents Chemother 2001, 45:2331-2339.
95. Barnaud G, Labia R, Raskine L, Sanson-Le Pors MJ, Philippon A, Arlet G. Extension of resistance to cefepime and cefpirome associated to a six amino acid deletion in the H-10 helix of the cephalosporinase of an Enterobacter cloacae clinical isolate. FEMS Microbiol Lett 2001, 20:185-190.
96. Barlow M, Hall BG. Experimental prediction of the evolution of cefepime resistance from the CMY-2 AmpC beta-lactamase. Genetics 2003, 164:23-29.
97. Barnaud G, Benzerara Y, Gravisse J, Raskine L, Sanson-Le Pors MJ, Labia R, et al. Selection during cefepime treatment of a new cephalosporinase variant with extended-spectrum resistance to cefepime in an Enterobacter aerogenes clinical isolate. Antimicrob Agents Chemother 2004, 48:1040-1042.
98. Morosini MI, Negri MC, Shoichet B, Baquero MR, Baquero F, Blazquez J. An extended-spectrum AmpC-type beta-lactamase obtained by in vitro antibiotic selection. FEMS Microbiol Lett 1998, 165:85-90.
99. Mammeri H, Poirel L, Bemer P, Drugeon H, Nordmann P. Resistance to cefepime and cefpirome due to a 4-amino-acid deletion in the chromosome-encoded AmpC beta-lactamase of a Serratia marcescens clinical isolate. Antimicrob Agents Chemother 2004, 48:716-720.
100. Doi Y, Wachino J, Ishiguro M, Kurokawa H, Yamane K, Shibata N, et al. Inhibitor-sensitive AmpC beta-lactamase variant produced by an Escherichia coli clinical isolate resistant to oxyiminocephalosporins and cephamycins. Antimicrob Agents Chemother 2004, 48:2652-2658.
101. Gonzalez Leiza M, Perez-Diaz JC, Ayala J, Casellas JM, Martinez-Beltran J, Bush K, et al. Gene sequence and biochemical characterization of FOX-1 from Klebsiella pneumoniae, a new AmpC-type plasmid-mediated beta-lactamase with two molecular variants. Antimicrob Agents Chemother 1994, 38:2150-2157.
102. Bauernfeind A, Wagner S, Jungwirth R, Schneider I, Meyer D. A novel class C beta-lactamase (FOX-2) in Escherichia coli conferring resistance to cephamycins. Antimicrob Agents Chemother 1997, 41:2041-2046.
103. Marchese A, Arlet G, Schito GC, Lagrange PH, Philippon A. Characterization of FOX-3, an AmpC-type plasmid-mediated beta-lactamase from an Italian isolate of Klebsiella oxytoca. Antimicrob Agents Chemother 1998, 42:464-467.
104. Bou G, Oliver A, Ojeda M, Monzon C, Martinez-Beltran J. Molecular characterization of FOX-4, a new AmpC-type plasmid-mediated beta-lactamase from an Escherichia coli strain isolated in Spain. Antimicrob Agents Chemother 2000, 44:2549-2553.
105. Queenan AM, Jenkins S, Bush K. Cloning and biochemical characterization of FOX-5, an AmpC-type plasmid-encoded beta-lactamase from a New York City Klebsiella pneumoniae clinical isolate. Antimicrob Agents Chemother 2001, 45:3189-3194.